General functioning: Average endpoint general functioning score (clinically improved) (no data) · people with treatment‐resistant schizophrenia
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ generalised onset Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Mental state: General ‐ clinically important change (no improvement) · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes mental state: General ‐ clinically important change (no improvement)… compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes adverse events: General: any adverse event compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Quality of life: 1. General quality of life · patients with schizophrenia
1 finding from 1 review
Mental state: General ‐ clinically important change (no improvement) · patients with schizophrenia
CBT showed no clear difference in mental state: General ‐ clinically important change (no improvement) compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Generic quality of life measures · chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Generic HRQL (change from baseline) · chronic rhinosinusitis
2 findings from 1 review
no estimate extracted
Studies not reported
Low
no estimate extracted
Studies not reported
Low
Intervention not reported
Mental state: general ‐ average endpoint score (PANSS, high score = poor) ‐ medium term, ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review